-
Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock
Monday, July 17, 2017 - 12:52pm | 1010Read More...Verastem Inc (NASDAQ: VSTM) stock had a relatively flat month in June despite the firm’s presentation of positive follow-up data for its DYNAMO study of Duvelisib, its PI3K-delta and gamma inhibitor for patients with follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and marginal...
-
Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
Thursday, January 19, 2017 - 1:29pm | 1018Read More...Verastem Inc (NASDAQ: VSTM) is a biopharmaceutical company that focuses on discovering and developing therapies for the treatment of patients with cancer. Verastem acquired a license agreement from Infinity Pharmaceuticals granting Verastem exclusive worldwide rights to develop and...
-
Stocks Hitting 52-Week Highs (CPEX, IRDMZ, JSDA, LPSB)
Wednesday, June 2, 2010 - 1:54pm | 251Read More...CPEX Pharmaceuticals Inc (NASDAQ: CPEX) crossed its earlier 52-week high of $26.65 and created a new 52-week high of $26.85. CPEX’s shareholders have recently elected Robert Forrester, COO of Forma Therapeutics, to the company’s board of directors. Iridium Communications Inc (NASDAQ: IRDMZ) was...
